The Value of FDG-PET/CT in the Post-Treatment Evaluation of Endometrial Carcinoma: A Comparison of PET/CT Findings with Conventional Imaging and CA 125 as a Tumour Marker
dc.contributor.author | Özcan Kara, P. | |
dc.contributor.author | Kara, T. | |
dc.contributor.author | Kaya, B. | |
dc.contributor.author | Kara Gedik, G. | |
dc.contributor.author | Sarı, O. | |
dc.date.accessioned | 2020-03-26T18:31:55Z | |
dc.date.available | 2020-03-26T18:31:55Z | |
dc.date.issued | 2012 | |
dc.department | Selçuk Üniversitesi | en_US |
dc.description.abstract | Objectives: This retrospective study was designed to assess the value of positron emission tomography/computed tomography imaging (PET/CT) in the post-treatment evaluation of the patients with endometrial carcinoma and to compare PET/CT scan with conventional imaging (Cl) including computed tomography (CT), ultrasonography (US) and magnetic resonance imaging (MRI) and CA 125 with both 20 U/ml and 35 U/ml cut-off values. Materials and methods: A total of 31 patients who were treated for histopathologically proven endometrial adenocarcinoma, underwent PET/CT examination for restaging and suspected recurrence. Thirty five PET/CT studies were performed in 31 patients. Lesion status was determined on the basis of clinical follow-up including radiological imaging (follow-up CT scan) at least 6 months and response to therapy. Results: Of the 35 PET/CT studies, 13 (37%) studies were positive, whereas 22 (63%) of them were negative. On study-based analysis the overall sensitivity, specificity, accuracy for PET/CT imaging were 100%, 96% and 97%, respectively. The corresponding information for Cl were 46%, 87% and 74%, for CA 125 (cut off= 20 U/ml) measurement were 45%, 88% and 74%, and for CA 125 (cut off = 35 U/ml) measurement were 27%, 100% and 78%, respectively. On lesion-based analysis, PET/CT revealed only one false positive case. In none of 21 patients with negative 22 PET/CT studies, no subsequent clinical or radiological recurrences were observed with a follow-up of at least 6 months. Conclusion: FDG-PET/CT is found more useful modality than CI and CA 125 in the evaluation of post-treatment endometrial carcinoma patients, for suspected recurrence. | en_US |
dc.identifier.citation | Özcan Kara, P., Kara, T., Kaya, B., Kara Gedik, G., Sarı, O., (2012). The Value of FDG-PET/CT in the Post-Treatment Evaluation of Endometrial Carcinoma: A Comparison of PET/CT Findings with Conventional Imaging and CA 125 as a Tumour Marker. Revista Espanola De Medicina Nuclear E Imagen Molecular, 31(5), 257-260. DOI:10.1016/j.remn.2011.06.001 | |
dc.identifier.doi | 10.1016/j.remn.2011.06.001 | en_US |
dc.identifier.endpage | 260 | en_US |
dc.identifier.issn | 2253-654X | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.pmid | 23067527 | en_US |
dc.identifier.scopusquality | Q3 | en_US |
dc.identifier.startpage | 257 | en_US |
dc.identifier.uri | https://dx.doi.org/10.1016/j.remn.2011.06.001 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12395/28572 | |
dc.identifier.volume | 31 | en_US |
dc.identifier.wos | WOS:000309022100004 | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.institutionauthor | Özcan Kara, P. | |
dc.institutionauthor | Kara Gedik, G. | |
dc.institutionauthor | Kaya, B. | |
dc.institutionauthor | Sarı, O. | |
dc.language.iso | en | en_US |
dc.publisher | ELSEVIER DOYMA SL | en_US |
dc.relation.ispartof | Revista Espanola De Medicina Nuclear E Imagen Molecular | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.selcuk | 20240510_oaig | en_US |
dc.subject | Endometrial Carcinoma | en_US |
dc.subject | FDG-PET/CT | en_US |
dc.subject | CA 125 | en_US |
dc.title | The Value of FDG-PET/CT in the Post-Treatment Evaluation of Endometrial Carcinoma: A Comparison of PET/CT Findings with Conventional Imaging and CA 125 as a Tumour Marker | en_US |
dc.type | Article | en_US |
Dosyalar
Orijinal paket
1 - 1 / 1
Yükleniyor...
- İsim:
- 28572.pdf
- Boyut:
- 246.18 KB
- Biçim:
- Adobe Portable Document Format
- Açıklama:
- Makale Dosyası